<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between August 1984 and September 1990, 13 children with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) were treated with ALL high-risk protocol (5 with TCLSG 842 regimen and 8 with TPOG 882B protocol) at Taichung Veterans General Hospital </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnosis of NHL was confirmed by histology </plain></SENT>
<SENT sid="2" pm="."><plain>Nine had lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, three had histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one had small non-cleaved cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, according to the Rappaport classification </plain></SENT>
<SENT sid="3" pm="."><plain>After thorough clinical evaluation eight children were NHL stage IV; four were stage III; and one was stage II </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these children had received chemotherapy as <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL) high-risk protocol for a total of three years, including central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 13 patients, 9 (69.2%) gained complete remission </plain></SENT>
<SENT sid="6" pm="."><plain>Over-<z:hpo ids='HP_0000001'>all</z:hpo> survival rate was 46.2%, with a median interval of 36 months </plain></SENT>
<SENT sid="7" pm="."><plain>The complete remission rate and survival rate for the nine children with lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was better at 77.7% &amp; 66.6% respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Within the nonresponsive group, two failed to remit because of early withdrawal from the protocol; the other two patients were refractory to treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Relapse was noted in one patient </plain></SENT>
<SENT sid="10" pm="."><plain>As to the side effects, neutropenic <z:hpo ids='HP_0001945'>fever</z:hpo> was the most common problem encountered (9 occurrences in 13 patients) </plain></SENT>
<SENT sid="11" pm="."><plain>Other major complications included severe mucositis, massive GI <z:mp ids='MP_0001914'>bleeding</z:mp>, intracranial <z:mp ids='MP_0005048'>thrombosis</z:mp> induced by l-asparaginase and <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0220612" disease_type="Neoplastic Process" abbrv="">Childhood NHL</z:e> is often of diffuse types in pathology, and most affected children have advanced diseases at diagnosis </plain></SENT>
<SENT sid="13" pm="."><plain>Choosing an optimal treatment protocol is important for good treatment results </plain></SENT>
</text></document>